An anti-inflammatory drug from Novo Nordisk unexpectedly failed in a Phase 3 study that aimed to prove a link between cardiovascular inflammation and heart disease.
Elizabeth Cairns is a Senior biopharma journalist at Informa. She covers a wide range of topics within the realms of medicine and healthcare, including pharmaceuticals, health and wellness, healthcare technology, and the intersection of AI and machine learning in the industry. Elizabeth's insights and expertise have been featured in prominent publications such as Citeline and Endpoints News.
